trending Market Intelligence /marketintelligence/en/news-insights/trending/KfMWBXYzb0pryACOylEpDg2 content esgSubNav
In This List

Amgen-UCB's Evenity approved in EU to treat bone disorder

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Amgen-UCB's Evenity approved in EU to treat bone disorder

The European Commission approved Amgen Inc. and UCB SA's osteoporosis medicine Evenity in postmenopausal women at high risk of fracture.

Osteoporosis is a condition in which the bones become weak and brittle, and are prone to fractures.

The European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, recommended the medicine for approval in October, having originally rejected it in June.

The companies plan to begin the launch of the drug in the European Economic Area in the first half of 2020.

Evenity is approved in the U.S. and Canada for treating osteoporosis in postmenopausal women at high risk for fracture, and in Japan and South Korea for treating osteoporosis in women and men at high risk for fracture.

The drug is approved in the U.S. with a black-box warning — the U.S. Food and Drug Administration's highest risk alert — that cautions patients and prescribers regarding cardiovascular risk.